Percutaneous Balloon Aortic Valvuloplasty
Acute and 30-Day Follow-up Results in 674 Patients From the NHLBI Balloon Valvuloplasty Registry NHLBI Balloon Valvuloplasty Registry Participants Background. Percutaneous balloon aortic valvuloplasty has been used as a therapeutic option for relief of valvular stenosis. This study describes patients undergoing initial percutaneous aortic balloon valvuloplasty enrolled in the National Heart, Lung, and Blood Institute (NHLBI) Balloon Valvuloplasty Registry.
Methods and Results. Extensive baseline procedural and postprocedural data were tabulated in 674 patients during a 24-month period. Functional status was captured using standard methods and an overall functional scoring system. Complications were defined and divided into procedural, acute (within 24 hours), in-hospital, and within 30 days of the procedure. The patient population was elderly and symptomatic, with 83% >70 years of age. New York Heart Association functional class (FC) III or IV congestive heart failure (CHF) was present in 76%, syncope or presyncope was present in 34%, and Canadian Heart Association class III or TV angina was present in 23%. Using an overall functional scoring system (0-100), 54% exhibited scores <50. Comorbid disease was common. Forty-five percent possessed at least one serious noncardiac disability as a reason for valvuloplasty. Eighty percent of those seen by a cardiothoracic surgeon were believed inappropriate for aortic valve replacement. Hemodynamically, the aortic valve area increased from 0.5+±0.2 cm2 to 0.8+±0.3 cm2 (p<0.0001), accompanied by a fall in mean and peak aortic valve gradient from 55+21 and 65+±28 mm Hg to 29±+13 and 31±18 mm Hg, respectively (both p <0.0001). Small but significant increases were observed in cardiac output, heart rate, and mean aortic pressure with minor declines in the pulmonary artery (PA) systolic and left ventricular (LV) end-diastolic pressure. One hundred sixty-seven (25%) experienced at least one significant complication within 24 hours, and 211 (31%) experienced a significant complication before discharge. Complications before hospital discharge included the need for transfusion (23%), vascular surgery (7%), cerebrovascular accident (3%), other systemic embolus (2%), myocardial infarction (2%), acute tubular necrosis (1%), or cardiac surgery (1%). Seventeen (3%) patients died during the procedure; 16 of those were due to cardiac causes. By hospital discharge, there was an additional 52 total deaths; 37 were due to cardiovascular causes. Between hospital discharge and 30 days, 23 additional deaths occurred; 18 were due to cardiac disease. At 30 days, therefore, there was a grand total of 92 (14%) deaths; 71 (11%) were due to cardiovascular-related causes. Univariate and logistic regression analysis of mortality revealed that death was most frequent in patients suffering multiorgan failure and poor LV-systolic function. Thirty-day mortality was associated with a predefined high-risk subset of hypotension and NYHA classIV CHF (risk ratio, 4.4), blood urea nitrogen (BUN) >30 mg/dl (risk ratio, 3.7), use of an antiarrhythmic (risk ratio, 2.9), and cardiac output <3.0 1/min (risk ratio, 2.4). Of the survivors (86%) at 30 days, symptomatic improvement was generally present. Seventy-five percent experienced at least one functional class improvement in CHF, and 53% experienced at least a quartile improvement in overall functional status score.
Conclusions. These data reveal that percutaneous aortic balloon valvuloplasty in an elderly and debilitated population can be done with low mortality but substantial morbidity. Mortality is greatestin patients with multiorgan failure resulting from poor cardiac output. In patients with reasonably preserved LV function who are otherwise inappropriate surgical candidates because of comorbid factors, survival and early improvement in symptomatic status are frequently observed after percutaneous aortic valvuloplasty. (Circulation 1991; 84:2383 -2397 Pe ercutaneous balloon aortic valvuloplasty (PBAV) has been introduced as a potential therapeutic option for relief of aortic valvular stenosis. Since the original description,t the procedure has become widespread in its application. Reports from the French registry23 and from large series in the United States4-6 have detailed initial hemodynamic and early follow-up results in up to 492 patients. The initial results from these studies and the data from several smaller series7-t0 have demonstrated variable efficacy and have generated uncertainty in the cardiology community regarding the role of this procedure in the care of patients with aortic stenosis. Accordingly, the use of PBAV has been the subject of numerous recent reviews and editorials. '1-22 In response to initial reports suggesting that PBAV may be a viable alternative to aortic valve replacement, the National Heart, Lung, and Blood Institute (NHLBI) initiated a registry for patients undergoing the procedure in the United States and Canada. This report details the baseline characteristics, acute hemodynamic results, procedural details, complications, and both early and 30-day follow-up of these patients.
Methods
Data entry began November 1, 1987 and was completed November 1, 1989 . This data collection commenced after completion of enrollment into the Mansfield Scientific Balloon Aortic Valvuloplasty Registry.5,6 Twenty-four clinical sites participated (see "Appendix"). During this 24-month period, 674 patients with aortic stenosis undergoing initial PBAV were enrolled in the Balloon Valvuloplasty Registry (BVR). During the interval of enrollment, the rate at which aortic valvuloplasty was being performed in the hospitals associated with the registry fluctuated (Figure 1 ). Only patients aged 18 years and older were enrolled. Both initial and repeat procedures were recorded, but only those patients who had an initial procedure are included in this report. A procedure was assumed to have been initiated the moment the skin was broken for intended valvuloplasty. All patients were enrolled under a protocol that required informed consent and approval from each participating site's institutional review board. Because this was a registry and not a controlled trial, no attempt was made to influence patient selection beyond that required by local standards of care.
Baseline data collection was prospectively entered on forms devised by subcommittees made up of the principal investigators involved in the BVR. An initial series of seven forms (patient information, history and current status, diagnostic angiography, echo-Doppler, hemodynamic data, procedural data, Month FIGURE 1. Graph shows rate of enrollment ofpatients into the Balloon Valvuloplasty Registry. Monthly breakdown from November 1987 to November 1989 is shown. A gradual decline in the rate of entry is evident as enthusiasm for the procedure waned. and hospital discharge information) were completed and forwarded to the clinical coordinating center at the University of Washington, Seattle.
At 5 weeks, each clinical site attempted to obtain telephone follow-up on all patients and completed a form detailing clinical status. A functional status form consisting of nine questions describing a series of routine tasks was completed at baseline and at follow-up. The patient was asked to respond to each question, and a point system was used wherein a score of 4 was assigned if the task could be performed with no difficulty, 3 if some difficulty, 2 if much difficulty, 1 if the patient could not perform the task because of health, and 0 if he could not perform the task for other reasons. The questions asked included taking care of oneself in general; moving in and out of the bed or chair; walking indoors; walking several blocks; walking one block or climbing one flight of stairs; doing light housework; doing errands such as grocery shopping, driving a car, or using public transportation; and doing vigorous activity or participating in strenuous sports.23 Using this system, the lower the overall score, the poorer the patient's overall functional status. Congestive heart failure (CHF) was described in accordance with the New York Heart Association criteria and graded from I to IV. 24 Angina was coded by Canadian Cardiovascular Class from 0 to IV.25 Syncope or near syncope and/or the presence of a systemic thromboembolic event existed if the event had occurred within the last 6 months. Mortality data were also collected, and a probable cause of death was assigned by a standing committee on mortality and morbidity. The probable cause of death was based on all available data, and a narrative was provided by the principal investigator involved.
The past medical history data set defined a series of illnesses based on routine clinical criteria. Hypertension, pulmonary disease, and diabetes mellitus required only that treatment for those conditions was necessary. Cerebrovascular disease included both cerebrovascular accidents and transient ischemic at-Supported by the National Heart, Lung, and Blood Institute, Bethesda, Md., contract NO1-HV-78100. 57 (9%) 59 (9%) 95 (14%) 152 (23%) 95 (14%) 254 (38%) 76 (11%) 112 (17%) *Overall, population is elderly with high incidence of comorbid disease processes. tacks. Peripheral vascular disease was present if claudication was noted. Significant renal insufficiency was defined as serum creatinine >2.0 mg/dl. Patients with functional class (FC) IV CHF and symptomatic hypotension (systolic blood pressure <100 mm Hg) were considered likely to be at highest risk and were prospectively analyzed as a group.
Most patients who underwent PBAV were at increased risk for surgical valve replacement or repair.
Both noncardiac and cardiac comorbid conditions were captured for analysis of these risks. If valvuloplasty was performed as a temporizing measure before aortic valve replacement, it was considered as a "bridge" procedure. Patient and physician preference were not mutually exclusive and were meant to further define the major reasons for performing aortic valvuloplasty instead of aortic valve replacement. The procedural data collected included the recording of the largest balloon diameters used, the total number of inflations, the duration of the longest inflation using the largest balloon sizes, and the combination of balloon sizes used when double balloon procedures were performed.
Angiographically, coronary artery disease was defined as a .70% diameter obstruction by visual estimate. Valvular calcium was subjectively assessed using a range from none to severely calcific. Aortic regurgitation and mitral regurgitation severity were graded by standard methods. 26 The angiographic left ventricular (LV) ejection fraction was frequently not measured because of the serious overall condition of many of these patients. Only 292 (43%) had a baseline ejection fraction reported; only 116 patients (17%) had an ejection fraction measurement by contrast ventriculography immediately after the procedure. Although extensive echocardiographic data were collected, only the global LV systolic function and the severity of aortic or mitral regurgitation are reported for the purposes of this study. Ventricular systolic function was qualitatively assessed by two-dimensional echocardiography and coded as normal, mildly reduced, moderately reduced, or severely reduced. The severity of valvular regurgitation was graded as none, mild, moderate, or severe, using either conventional pulsed or color Doppler flow mapping techniques. Pressure data were recorded by using either fluidfilled catheters or high-fidelity micromanometers. Cardiac output was measured by either Fick (26%), thermodilution (59%), or green dye (7%). In 7%, the data on the method of measurement of cardiac output were unavailable. The aortic valve area was determined by using either the Gorlin27 or the Hakki28 formula.
Statistical Analysis
Missing forms and missing data items resulted in reduced denominators for many variables. For some 
Major reasons for performing percutaneous aortic valvuloplasty were not mutually exclusive. "Bridge" procedure implies that eventual aortic valve replacement was the initial intention. Most patients underwent valvuloplasty procedure because of advanced age or some other comorbid factor. CNS, central nervous system. n =-672. tables, the number of submitted forms is given as an overall sample size. Percentages are based on all known values if the number of missing items is less than 5% of submitted forms. If 5% or more of the values are missing for a particular variable, the number of unknown values is indicated and included in the denominator.
Prevalvuloplasty and postvalvuloplasty hemodynamic results are compared using the paired t test. Mortality rates for patients with and without baseline risk factors were analyzed using x2 tests. Continuous data are presented as mean+1 SD.
Stepwise logistic regression models were fitted to identify important predictors of 30-day mortality. Baseline characteristics, preprocedure hemodynamic values, and procedure variables were considered. Only patients with known 30-day vital status were included in this analysis.
Results

Patient Characteristics
Tables 1 and 2 outline the baseline demographics of the population studied. The patient subset was elderly, with 83% of the patients greater than 70 years of age. Significant comorbid disease was also evident in many. Thirty-eight percent of the patients had renal insufficiency, 41% had hypertension, 20% had diabetes, 9% had dementia, 14% had peripheral vascular disease, and 17% had active neoplasm. Moderate or severe 176 (32%) Because of the importance of baseline left ventricular systolic function, echocardiographic measure of systolic function is included. When there were incomplete forms, the available number (n) is noted in the table. Only a small majority had coronary artery disease. Valvular calcium was common. Although mean ejection fraction was 48+19%, a wide range was present. Echocardiography data are presented that allow for comparisons at follow-up. n =648. Heart failure was common; 76% had NYHA FC III or IV symptoms. Six percent had both FC IV CHF and systemic hypotension (systolic blood pressure < 100 mm Hg). Angina was less common and present in only 38%, with 23% suffering from Canadian FC III or IV symptoms. Syncope or presyncope was present in about one third (34%). Using the overall functional status score, few patients (16%) scored greater than 75 and only 40% had scores greater than 50, again reflecting the general debilitated status of these patients. As might be expected, therapy for CHF was more commonly used than for angina.
The significance of these baseline characteristics in causing disability is further in evidence by noting the reasons given for proceeding to aortic valvuloplasty in lieu of aortic valve replacement (Table 3 ). Al- Data represent only those patients in whom paired data (both before and after valvuloplasty) were available. The available number (n) is noted for each value. In general, aortic valve gradient decreased by half and the valve area improved by 65%. LV, left ventricular; PA, pulmonary arterial. though old age clearly was the most common indication for valvuloplasty, significant coexistent multisystem disease was also very common. Because of age and comorbid disease, 84% of referring physicians or 86% of patients preferred aortic valvuloplasty over surgery. Surgical advice was sought in only 40% of patients; in those in whom it was obtained, surgery was recommended in only 20%. In almost half the patients (45%), a major contraindication to surgery was noncardiac disability.
Procedural Observations
The procedure was completed in 654 patients (97%). Single balloons were used in 89% of patients, with double balloons used in 11%. Two balloons were often used when there was an ineffective result from a single balloon procedure. Sixty-three percent of the time that two balloons were used, a single balloon was initially used. The 20 mm (56%) or 23 mm (37%) single balloon sizes were the most commonly used; 18 mm (2%) and 25 mm (5%) were less frequently used. One to three inflations were generally performed (68% of the time) with four to six inflations (27%) and more than six inflations (5%) less often required. The mean longest inflation time was similar for single (23-+±17 seconds) and double (24±14 seconds) balloon techniques . Using double balloons, the average diameter pair was 35±4 mm (range, [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] . The most common double balloons used were 15 and 18 mm (17% of the time), 15 and 20 mm (34%), and 20 and 20 mm (13%). Baseline Imaging and Catheterization Data Tables 4 and 5 describe the relevant imaging and hemodynamic data. About half of the patients had significant coronary artery disease. Aortic valvular calcification was commonly noted (79% with moderate or severe calcification). In those in whom the ejection fraction was available, the mean baseline value was 48+19%. Estimates of global function by echocardiography revealed that 36% had moderately or severely reduced global LV systolic function. By Doppler echocardiography, moderate or severe aortic regurgitation was uncommon (17%), but moderate or severe mitral regurgitation was present in about one third (32%). Results of the Valvuloplasty Procedure As described in Table 5 , the baseline mean aortic valvular gradient fell from 55+21 mm Hg to 29+13 mm Hg after the procedure. A greater than 25 mm Hg decrease in mean gradient after aortic valvuloplasty was observed in 43% of patients. The aortic valve area increased from 0.5+±0.2 cm2 to 0.8+0.3 cm2 (p<0.0001). In most patients (77%), the increase in valve area was <0.4 cm2. The final aortic valve area was .0.8 cm2 in 351 patients (55%) and .1.0 cm2 in 181 patients (29%). In 81 (13%) there was either no change or . 0. 1 cm2 improvement in aortic valve area. In two patients, a worsening of the aortic valve area was reported.
Because of the large sample size, statistically significant differences in certain hemodynamics were observed even when the mean differences were clinically small. This was true for cardiac output, mean aortic pressure, pulmonary artery pressure, and heart rate. A more obvious and clinically relevant difference was observed in the mean LV systolic pressure after the procedure, in which a fall from 196±39 mm Hg to 172±32 mm Hg was observed.
The change in valve area after a single balloon procedure was 0.32+0.22 cm2 and this was insignificantly greater than after a double balloon procedure (0.26+0.17 cm2; p =0.06). This disparity likely reflects the fact that double balloons were usually used after failure of the single balloon technique, although in some centers double balloons were preferentially used. In contrast to the aortic valve area, there was a greater decrease in the transvalvular gradient after the use of double balloons compared with a single balloon (32+22 mm Hg versus 26+16 mm Hg, p=0.02). Table 6 describes the complications that occurred in the laboratory or within 24 hours of the procedure. During the first 24 hours, at least one complication of any severity occurred in 382 patients (57%). Significant complications (identified by an asterisk in the table) occurred in 167 patients (25%).
Complications Beginning in the Laboratory
The most common minor procedural complication was balloon rupture, occurring in 111 patients (17%). However, sequelae from balloon rupture occurred in only three patients (0.5%). The final aortic valve area (AVA) in patients in whom the balloon ruptured was 0.9+0.4 cm2, which was similar to the group in whom balloon rupture did not occur (0.8±0.3 cm2).
A variety of significant complications occurred. Death occurred in the laboratory in 17 patients (3%). In seven patients, the procedure had been completed. Death was secondary to cardiogenic shock in 12, with one death attributable to each of the following: LV perforation, pulmonary artery rupture from a Swan-Ganz catheter, arrhythmia, sudden death, and myocardial infarction. Specific hemodynamic complications occurred in 85 patients (13%), including prolonged hypotension in 8% and the need for cardiopulmonary resuscitation in 4%. Perforation leading to cardiac tamponade and pericardiocentesis occurred in 10 patients as well. Acute valvular insufficiency occurred in seven patients (1%), with aortic insufficiency in six and BVR acute mitral regurgitation in one. Intra-aortic balloon counterpulsation was used in 11 patients (2%). Embolic events were rare. Acute focal neurological deficits were described in only 13 patients (2%), with other systemic embolization in only 11 (2%). Arrhythmias requiring therapy were seen in 64 patients (10%). Although bundle branch block was generally transient, it persisted in 5% of patients throughout the procedure. Atrioventricular block requiring pacing occurred in 4% of patients and direct current cardioversion was necessary for either ventricular tachycardia or fibrillation in 3%. Angina (1%) and acute myocardial infarction (1%) were not common occurrences.
Hematoma and the need for blood transfusion represented the most common postprocedural complication, with 20% of patients requiring at least one unit of blood or blood products. Thirty-five patients (5%) required vascular surgery of the access artery (although this was an elective practice procedure in some institutions and probably overrepresents the actual incidence of vascular injury).
In-Hospital Complications and Clinical Status at Discharge
Patients were discharged from the hospital after an average stay of 12.0±12.8 days (range, 0-129 days). After the valvuloplasty procedure, the average patient stay was 7.6±10.0 days (range, 0-126 days). Figure 2 outlines the acute complications related to the procedure (<24 hours) and those that occurred later during the hospital stay. A significant clinical complication occurred during hospitalization in 211 patients (31%). Eight percent of patients suffered cardiac death and 2% noncardiac death before discharge. A complication of any severity occurred in 412 patients (61%) after aortic valvuloplasty.
At the time of discharge, 456 patients (68%) were improved from a cardiovascular standpoint and 366 (55%) were improved overall. No improvement in cardiovascular symptoms was observed in 133 patients (20%), and no improvement for overall status was observed in 219 (33%). Excluding deaths, only two patients (0.3%) were reported worse from a cardiovascular assessment, and only eight patients (1%) were reported worse overall.
Follow-up Mortality and Clinical Status
Cumulative mortality data are presented in Table  7 . After discharge from the hospital, an additional 23 patients died before the 30-day anniversary. This results in a cumulative 30-day mortality rate of 92 of 643 (14%). Of the total deaths, 71 (11%) were considered cardiovascular. Table 8 examines the univariate associations between baseline characteris- tics and 30-day mortality. Significantly higher mortality rates are seen in patients who had a prior myocardial infarction and among those who suffer from the consequences of low cardiac output. The complex of both CHF and hypotension identified a particularly high-risk subset.
Using multivariable logistic regression analysis, the major identifiers of 30-day mortality are outlined in Table 9 . Patients who were systemically the most ill were clearly at greatest risk for early death. The high risk subset with cardiogenic shock, a blood urea nitrogen (BUN) >30, the need for an antiarrhythmic agent, or the presence of a low cardiac output (<3.0 1/min) were all identified as independent predictors of poor 30-day outcome. Figure 3 describes the follow-up functional status of 484 survivors at the 30-day follow-up stratified by the baseline NYHA functional class for CHF (upper panel) and the derived overall functional class score (lower panel). Three hundred sixty-four of the survivors (75%) experienced at least one NYHA functional class improvement in symptoms of heart failure or were unchanged if the baseline functional class was I. Using the functional class scoring system, 257 (53%) noted at least a one-quartile improvement or remained in the highest quartile of the overall functional score. Thus, the majority of survivors experienced early symptomatic and functional improvement after the valvuloplasty procedure. Discussion These data confirm that PBAV can usually be performed even in an extremely ill patient population and that a definite hemodynamic improvement is measurable in almost all patients. The overall changes in the aortic valve area and mean aortic gradient (Table 5 ) are similar to those reported in other series. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] 17, [29] [30] [31] [32] In general, the mean valvular gradient tends to be reduced by half and the aortic valve area increased by about 65%. The final aortic valve area frequently remains in the 0.7-0.9 cm2 range, however, and this may have had an impact on the enthusiasm for PBAV at the clinical sites during the time course of the registry (see Figure  1 ). As seen in this figure, enrollment of patients declined during the course of this study as data regarding the often inadequate long-term clinical and hemodynamic results were reported.241132-36 Data derived from the Mansfield Registry of 492 elderly symptomatic nonsurgical patients with severe aortic stenosis reveals a 1-year survival rate of 64% and an event-free survival of 43%.36 In this population, recatheterization of 95 patients at 6 months after PBAV demonstrated that a reduction in valve area toward baseline occurred in 62% of improved patients and 80% of recurrently symptomatic patients. 35 The definition of a "successful" procedure must await long-term studies because early clinical improvement is sometimes seen even in patients with minimal (0.1-0.2 cm2) changes in the measured aortic valve area. Whether these modest changes might improve symptoms or survival by improving myocardial oxygen demand after PBAV is certainly conjectural. The final valve area after PBAV does not appear to be predictive of early symptomatic improvement. In the absence of hard data regarding the correlation of final AVA to clinical response and given the imprecision of measuring valve area accurately, particularly in patients with low cardiac output, any definition of success is bound to be an arbitrary one.
It is important to emphasize that this is a registry report and not a controlled trial. Indeed, there are few data against which these results can even be compared. O'Keefe et al,37 in a retrospective review of 50 patients with severe aortic stenosis (mean age, 77 years) in whom no surgery had been performed, found a dismal outcome, with actuarial survival at 1, 2, and 3 years of 57%, 37%, and 25%, respectively. This contrasts to an age-and sex-matched control subject group wherein survival was 93%, 85%, and 75%, respectively. Given the elderly age of the BVR patients and the high prevalence of significant comorbid disease, one must assume that the majority of patients in this registry were at substantial risk for a poor outcome without some intervention, and many had a poor prognosis regardless of the presence of severe aortic stenosis. However, a prospective randomized study comparing valvuloplasty versus medical therapy would be necessary to define the true potential survival benefit from PBAV. Surgery may have been an appropriate option for some of these patients. When a surgical opinion was requested, however, 80% of the patients were not considered surgical candidates. In a recent review of surgical outcomes in octogenarians,38 it was observed that many elderly patients can certainly undergo aortic valve replacement at an acceptable surgical risk; a high percentage (up to 60%), however, experience postoperative morbidity, and this concern weighs heavily in favor of an alternative approach. In a review of one institution's experience with aortic valve re- Four major identifiers were observed. The highest-risk subset (risk ratio, 4.4) was the group with hypotension and congestive heart failure. A high BUN, the use of an antiarrhythmic, and a cardiac output <3.0 1/min also contributed independent risk toward fatal outcome. FC, functional class; CHF, congestive heart failure; BUN, blood urea nitrogen. placement and PBAV, Acar et al17 noted an aortic valve replacement operative mortality of 6.2% in patients over the age of 70 with a relatively encouraging 5-year survival of 67.5%. Thus, chronological age alone is certainly not a clear criteria for exclusion of patients for surgical aortic valve replacement.
The concept that either surgical valvuloplasty or balloon valvuloplasty procedures can be an effective therapy in patients with aortic stenosis has yet to be resolved. Surgical valvotomy is often considered the procedure of choice for congenital aortic stenosis in the pediatric age range. In a recent review of 1,136 patients, including 40 of their own, Mackworth-Young and colleagues39 emphasized that overall excellent results can generally be achieved in these young patients. Other reports have confirmed this as well,40,4' but none are applicable to the population in this registry. More germane to this patient population is the use of surgical valvotomy for acquired aortic stenosis, using either open surgical excision42 or ultrasonic debridement. 43 Although there remains some enthusiasm for those latter two approaches in adults, the moderate incidence of restenosis and the relatively high incidence of eventual aortic regurgitation has led most surgeons to abandon these procedures. Thus, there is no comparable surgical cohort with which to compare the patient population in the BVR. Given the high risk for surgery in most of these elderly patients, it is equally unlikely that a randomized trial of valvuloplasty versus surgery will ever be achievable.
The literature would suggest that percutaneous aortic valvuloplasty can be an effective tool in settings other than the elderly, nonsurgical candidate. Besides its use in pediatrics and neonates,44-52 even after a prior surgical valvotomy,53 the approach has also found a role in "bailing out" patients in cardiogenic shock related to aortic stenosis.54 It can also be an effective bridge to future aortic valve replacement. This latter role, in fact, is an increasingly important consideration (in 7% of the BVR patients this was the goal). Percutaneous balloon aortic valvuloplasty has likewise been advanced as a means of reducing the risk of noncardiac surgery in patients with severe aortic stenosis.55 The technique has also been applied in the setting of pregnancy,56 and combined procedures with PBAV such as percutaneous coronary angioplasty57,58 and mitral valvotomy59 have also been shown to be feasible.
Procedural Observations
There is evidence from other studies that the use of two balloons may be useful when a single balloon is ineffective,31,60 and there may be an inherent advantage to the use of bifoil or trefoil designs61-63 by allowing systemic pressure to be better maintained during balloon inflation. Reported complication rates from overdilating the aortic valve annulus, though, have produced conflicting results, with some authors implying that this can be done safely64 but others cautioning against this because of the very real danger of aortic annular rupture. 65 26-50; light gray, 51-75; white, 76 -1 00). The higher the score, the less disability experienced. Using either the NYMA functional class method or the overall scoring system, it is evident that many patients were substantially improved at 30 days.
mented, four of the patients had the procedure performed with a 23-mm single balloon and two patients with double balloons. Thus, it seems wise to avoid overdilating the aortic annulus in an elderly patient population such as this. Although the retrograde approach was used primarily in this registry, the antegrade approach via transseptal catheterization can be effective, and there was no evidence from the BVR that results are different when this latter technique is used. The use of the antegrade approach may also reduce vascular complications,71 and, given the severity of peripheral vascular disease in many of these elderly patients, this Number Patients _ approach does provide an option that appears effective and safe with those familiar with this technique.
Other options, such as the use of general anesthe-sia72 or partial cardiopulmonary bypass,73 have also been applied as adjuncts during aortic valvuloplasty, but these data suggest that the majority of even extremely ill patients can undergo the PBAV without these extraordinary and costly means of support during the procedure.
Acute Complications
Several broad observations are relevant regarding the complications observed. Given the severity of the disease processes, complications from the procedure appear to be within reasonably acceptable limits. Table 6 and Figure 2 summarize these complications. Aortic regurgitation was uncommon. This is similar to reports that have used quantitative methods74 to better define severity. When aortic regurgitation does occur, it can be catastrophic, however. Acute aortic regurgitation occurred in six patients in the registry, causing death in two and surgery in four (including three patients emergently). Aortic regurgitation can result from either rupture of the aortic annulus65-70 or leaflet eversion. 75 Embolic events were surprisingly infrequent. This may be due to the extensive endothelialization of calcium deposition present pathologically on many of these stenotic valves. However, embolic events may be silent,76 so the true incidence of emboli is likely underrepresented. Acute myocardial infarction, a known complication,77 was seen in only 10 patients.
One patient developed acute mitral regurgitation presumably caused by laceration of the attachment of the anterior leaflet to the aortic annulus.78 A similar complication has been reported in a patient in whom aberrant mitral chordae were apparently ruptured. 79 Because of the age of these patients and the presence of extensive vascular disease, hematoma and pseudoaneurysm formation would be anticipated risks. Vascular surgery was performed acutely in 35 patients (5%) and during the hospitalization in another 12 patients. The large size of these balloons or sheaths within the femoral artery clearly puts these elderly patients at risk for bleeding complications. When sheaths were used, 53% were 12F and 38% were 14F. Newer balloon catheters now allow the use of 1OF sheaths. In addition, mental confusion and arthritic complaints often result in considerable difficulty in maintaining prolonged immobility and effective hemostasis after the procedure. It is not surprising that vascular complications and the need for blood transfusion was a relatively frequent occurrence, therefore. Accordingly, some groups have suggested an open exposure of the femoral artery for insertion of the PBAV catheters. 80 The advent of newer low-profile balloon catheters may decrease the incidence of these complications. The identification of these complications when they occur appears to be improved by use of Doppler color-flow imaging.81
Persistent bundle branch block occurred in 5% and is most likely the result of direct trauma to the conduction system below the AV node. 82 Atrioventricular block requiring pacing occurred in 4%. Other arrhythmias, predominantly ventricular, were seen in a larger number of patients (10%), with one death resulting from an undefined arrhythmia. In 3% of patients, ventricular fibrillation or ventricular tachycardia occurred, requiring countershock or cardioversion. Antiarrhythmic therapy was identified as one of the major contributors to a poor 30-day outcome, but it could not be determined whether this was related to the underlying arrhythmia or the proarrhythmic effects of the antiarrhythmic agents.
Less common complications include protamine reactions in three patients, fever in two, a ventricular septal defect in one, and the rupture of a pulmonary artery caused by a right heart catheter in one. Sporadic reports of complications not observed in this registry have included bacterial endocarditis,83 hyponatremia,84 acute disseminated intravascular coagulopathy,85 and fracture of a guide wire.86
Acute Hemodynamic Results
Despite reports of no gross observational changes in the aortic valve at surgery after the use of balloon catheters,87 it is clear that balloon valvuloplasty does result in an acute reduction in the valvular gradient and an acute increase in the effective aortic valve orifice area. The inflation of an occluding balloon in the aortic outflow results in a transient reduction in the aortic pressure and subsequent marked rise in left ventricular pressure. Flow around the balloon or balloons allows for some ejection in most patients, however. The reduction in coronary perfusion pressure and the increased wall stress often results in increasing myocardial oxygen demands, and transient myocardial ischemia can be documented by studies of coronary sinus flow and metabolism.8889 Hemodynamically, this is reflected in prolongation of early diastolic relaxation (r). 90 Concurrent with this brief ischemic period is the reduction in afterload evident from the improvement in AVA. In this report, the final AVA was 0.8+0.3 cm2, still consistent with moderate aortic stenosis. Reflex vasodilation, possibly caused by baroreceptor stimulation or the release of certain humoral factors,91,92 may also help to reduce afterload. Associated vasodilation and blood loss combine to reduce preload, and this effect is reflected in these data by a reduced LV peak systolic pressure and a decrease in both LV end-diastolic volume and pressure.
Aortic valvuloplasty thus results in acute afterload reduction, acute preload reduction, and brief myocardial stunning. The hemodynamic results in any one patient are obviously a reflection of the contribution of each of these factors. The culmination of these factors results in the ejection fraction rising or remaining unchanged after the procedure, with cardiac output generally increasing by only a small amount ( Table 5 ). The small, early rise in ejection fraction has been shown to continue rising along with the gradient in the next few days after the procedure,93-95 likely resulting from a gradual improvement in stroke volume in the early days after the procedure. The mean baseline ejection fraction of 48+19% likely overestimates the actual ejection fraction in the entire population because many with severe LV dysfunction did not undergo contrast ventriculography.
In-Hospital and 30-Day Morbidity and Mortality Tables 7, 8 , and 9 summarize the mortality data. Acutely, 16 patients died from a cardiovascular cause, with 37 more suffering cardiac death in the hospital. Thus, 53 patients (8%) died from cardiac events before discharge. Sixteen additional deaths (2%) occurred in-hospital from noncardiovascular complications. Within the first 30 days after discharge, an additional 23 patients (3%) died. Thirtyday mortality from all causes, therefore, was present in 92 patients (14%), with 71 patients dying (11%) from cardiovascular events. As these data should be compared with surgical valve replacement series, 30-day mortality figures are appropriate. As shown in Table 9 , death was usually related to the general severity of illness experienced by these elderly patients. The highest risk population would be expected to be those with both hypotension and severe CHF. This was indeed the case, with a 49% mortality observed in this select subset.
Thus, it may be of questionable value to consider percutaneous aortic valvuloplasty in patients exhibiting these high-risk characteristics. Although this registry does not have a comparative cohort of patients treated medically or with aortic valve replacement, the data suggest poor left ventricular pump function, and the consequences of poor perfusion independently predict a poor outcome. Other series have also suggested that elevated right heart and pulmonary pres-sures96 and a low left ventricular ejection fraction32,97 are associated with poor short-term and 1-year outcomes. Despite the afterload mismatch evident in these patients, a measure of contractile function, such as the ejection fraction, still appears to be a key predictor of survival. Not all series have found a reduced ejection fraction to be limiting, however, with relatively good results reported from the French literature in patients with an ejection fraction <40% in whom 1-year follow-up was available.33 Certain subsets with low output and low valve gradients have also been found to be clinically well at 8.8 months.98 In the 86% who do survive to 30 days, it is clear that symptomatic improvement is enjoyed by most. Figure 3 displays the results of the analysis of both the classic NYHA functional class improvement and the overall functional scoring system used in this registry. Three hundred sixty-four were improved regarding heart failure symptoms, and 257 were improved using the functional scoring system. Improvement was often dramatic in individual cases. Thus, although it is clear that the most seriously ill patients had the greatest mortality, the overwhelming majority of patients did not fall into the high-risk category, and they experienced at least some functional improvement.
Conclusions
This study reinforces the use of PBAV for improving the quality of life for elderly patients in whom a surgical alternative is a poor or unacceptable option. Even if restenosis is inevitable, as has been suggested in some series,343599 when the high morbidity and mortality associated with either undergoing no procedure or with use of aortic valve replacement in these elderly patients is considered, short-term symptomatic relief would appear to be a reasonable outcome that can be achieved with the use of percutaneous aortic valvuloplasty techniques. This improvement is most likely to occur in those symptomatic patients who have yet to develop an associated cardiomyopathy and generalized debilitation. In patients with preserved LV function, who are otherwise not appropriate surgical candidates, early improvement in symptomatic status is frequently observed. 
